30-yr Course and Favorable Outcome of Alveolar Echinococcosis Despite Multiple Metastatic Organ Involvement in a Non-immune Suppressed Patient

Karine Bardonnet; Dominique A Vuitton; Frédéric Grenouillet; Georges A Mantion; Eric Delabrousse; Oleg Blagosklonov; Jean-Philippe Miguet; Solange Bresson-Hadni


Ann Clin Microbiol Antimicrob. 2013;12(1) 

In This Article


In the 1970s, in the patients with AE, life expectancy was estimated to be reduced by 18.2 and 21.3 years for men and women respectively; by 2005 it was reduced by approximately 3.5 and 2.6 years, respectively.[19] Continuous ABZ has greatly contributed to prolonged survival.[12,20] Presence of metastasis is generally considered of poor prognosis in AE; a recent study on 387 French patients confirmed that it was actually associated with higher AE-specific mortality.[12] Moreover, multiple extra-hepatic locations of AE are usually associated with immune suppression.[8] The history of the AE patient we are reporting suggests that multi-organ involvement and AE recurrence over time may occur in non-immune suppressed patients despite an apparently "radical surgery" which removed all visible AE lesions, and might be favored by a poor adherence to the benzimidazole chemotherapy. It also shows, however, that combined surgery and continuous administration of ABZ at high dosage may allow patients to survive more than 30 years after diagnosis despite multi-organ involvement.

Occurrence of metastatic locations of AE lesions is one of the hallmarks which justify the similarities between AE and malignant tumors, as exemplified by the PNM classification which parallels the TNM classification of tumors.[21] Invasion of neighboring organs and tissues ("N" in the PNM classification) by E. multilocularis progression from the initial liver location results in secondary lesions in the right lung through the diaphragm, in peritoneal and retroperitoneal cavities, hepatic pedicle, round ligament, right kidney and adrenal gland, pancreas, stomach or spleen. True metastases ("M" in the PNM classification) are mainly observed in the lung (7% of cases),[5] more rarely brain (3%), spleen (1%)[5] or bones (less than 1%),[6,22] in the skin[23] muscle,[24] heart,[24,25] and in any possible anatomical locations.[2] The clinical presentation of our patient combined all main 3 locations; the brain location was associated with orbit, eye, and facial/cranial bone involvement, which is per se very rare and was for that reason published several years ago.[26] In addition, metastases occurred along a 13-year period, from the patient's inaugural presentation with a lung metastasis in 1981 to the last discovery of another lung metastasis in 1993; meanwhile, brain, eye and bone locations were disclosed. In otherwise non-immune suppressed patients, genetic factors leading to poor cellular immunity and a marked trend to immune tolerance are statistically associated with the severity of AE, which includes metastasis formation,[27,28]e.g. HLA B8, DR3, DQ2 haplotype; however, this 'at risk' haplotype was not present in our patient which actually was HLA A11, A10; B13, B41; DR7, DR13; DQ2, DQ3. The main risk factor for disseminated AE is actually immune suppression. First observations were reported after liver transplantation for AE in patients who were not treated by benzimidazoles after receiving the liver graft.[29] Increase in residual extra-hepatic lesions as well as occurrence of brain or spleen metastasis were observed in a European series of 45 transplanted patients.[30] In the 1990s, such observations contributed to greatly reduce the indication of liver transplantation to treat AE.[3] Since then, AE occurrence in patients with kidney or heart transplantation has also been reported.[31,32] Rapidly progressing AE was also observed in AIDS[33,34] and it was suggested that pregnancy could be a tolerogenic situation which may have favored occurrence of brain metastasis.[35] Within the recent years, development of cancer chemotherapy and use of more potent immune suppressive drugs as well as immune modulating biological agents, especially anti-TNF compounds, have contributed to an increase in the number of disseminated and/or rapidly progressing "opportunistic AE" in patients with cancer, hematological disorders or chronic inflammatory diseases.[7,36,37] Our patient, however, all along his clinical course, did not present any overt - spontaneous or disease/treatment-related- immune suppression. There is no reason either to think that he was infected by an unusually virulent strain of E. multilocularis: several patients were diagnosed with slowly progressing, non-disseminated AE within a 30 km-range from his residence; and recent genetic analyses of E. multilocularis in the patient's endemic area do not favor major differences which might be responsible for more or less aggressive potential of the various strains.[38] Absence of the highly specific E. multilocularis 16–18 kDa band at Western Blot on the serum sampled in 1987, a few months before the first treatment withdrawal, was compatible with the negative ELISA results at that time, and thus with "inactive" lesions; however, "inactivity" was only temporary, as the following evolution well demonstrated.

First introduced in the pharmacopeia at the end of 1970s, benzimidazoles, although they do not kill E. multilocularis larvae, are the only drug available to treat AE and, being able to prevent metacestode growth and provided they are taken for life, have markedly contributed to improve AE patients' prognosis.[11,12,19] Albendazole, taken at the appropriate dosage of at least 15 mg/kg/day according a continuous schedule, is currently considered as the drug of choice.[4] Bad adherence to treatment, initial treatment with flubendazole which was later proved inefficient in AE, iterative switches from ABZ to MBZ because of side-effects, as well as insufficient dosage of ABZ due to the "discontinuous" schedule of administration recommended during the 1980–1990s[3] may have been the main reasons for repeated dissemination of AE lesions in the reported patient's. Adherence to treatment is essential and bad adherence, or ABZ withdrawal because of side-effects, have been shown to be crucial for lesion recurrence in patients with residual lesions after liver transplantation.[20] It is remarkable that, after 13 years of unreliable intake of the antiparasitic drugs tainted with successive extra-hepatic metastases of the disease, good adherence to ABZ treatment was followed by the inactivation of the lesions, negative PET-CT images and serology within 10 years, and a decision of definitive treatment withdrawal. The relative 'tolerance' of physicians in charge of the patient towards his bad adherence to treatment may also have been encouraged by the overconfidence of the surgeons about the complete resection of the initial lung and liver lesions. In addition, the absence of any reliability in the patient's allegations regarding last intake of the antiparasitic drug prevented them to measure ABZ sulfoxide plasma levels, which is, however, usually routinely performed in that reference center; MBZ measurements were not available when the patient switched to MBZ, which he did most of the time; and lower bioavailability of MBZ is well known.[3] Difficulties to assess completeness of the surgical resection and necessity to adjunct benzimidazoles even if resection was considered to be curative, were stressed as early as the 1980s[14,39] and were further highlighted by the observations of recurrence after liver transplantation.[30] Measurement of ABZ levels and proper interpretation of low levels of ABZ sulfoxide as evidence of bad adherence to treatment are also essential in the follow-up of AE patients.[4]

It is fortunate that our patient is still alive 30 years after the diagnosis of AE and 9 years after antiparasitic drug withdrawal; this observation confirms the therapeutic effectiveness of ABZ, despite its absence of parasitocidal effect, and possible withdrawal of the drug in highly selected subjects. Absence of FDG uptake at PET-CT assessment and negative Em2+ ELISA serology in 2011 suggest an aborting evolution of the parasitic lesions whatever the involved organ or tissue; persistence of the 26–28 kDa band at Western Blot is likely related to the persistence of non-viable parasitic tissue in various organs of the patient, as is often the case in AE patients with aborted lesions.[2] The current recommendations concern the "security margin" to be observed by the surgeons for the resection of AE lesions, similar to those recommended in oncological surgery, as well as the 2-yr ABZ continuous treatment which is mandatory in the so-called "radically operated on" patients.[4] Following these recommendations would have likely prevented the occurrence of the distant metastases and also radically changed our patient's quality of life.